Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Travere Therapeutics Inc (TVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/21/2025: TVTX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 18.81% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio - | 1Y Target Price 33.67 |
Price to earnings Ratio - | 1Y Target Price 33.67 | ||
Volume (30-day avg) 1789274 | Beta 0.84 | 52 Weeks Range 5.12 - 25.29 | Updated Date 04/23/2025 |
52 Weeks Range 5.12 - 25.29 | Updated Date 04/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -137.9% | Operating Margin (TTM) -79.34% |
Management Effectiveness
Return on Assets (TTM) -23.15% | Return on Equity (TTM) -246.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1440577262 | Price to Sales(TTM) 6.05 |
Enterprise Value 1440577262 | Price to Sales(TTM) 6.05 | ||
Enterprise Value to Revenue 6.18 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 88771696 | Shares Floating 75629404 |
Shares Outstanding 88771696 | Shares Floating 75629404 | ||
Percent Insiders 0.7 | Percent Institutions 109.22 |
Analyst Ratings
Rating 4.56 | Target Price 33.67 | Buy 3 | Strong Buy 11 |
Buy 3 | Strong Buy 11 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Travere Therapeutics Inc
Company Overview
History and Background
Travere Therapeutics Inc. was founded in 2011. It's a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Originally known as CymaBay Therapeutics, it shifted its focus and rebranded to Travere Therapeutics.
Core Business Areas
- Rare Kidney Diseases: Focuses on developing and commercializing therapies for rare kidney diseases like FSGS and IgAN.
- Rare Liver Diseases: Historically involved in developing therapies for rare liver diseases; currently focused on kidney diseases.
Leadership and Structure
Eric Dube is the CEO. The company has a typical biopharmaceutical organizational structure with departments for R&D, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Filspari (sparsentan): A dual endothelin angiotensin receptor antagonist indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Competitors include generic blood pressure medications and other therapies targeting IgAN progression. Market share data is still developing as Filspari is a relatively new therapy.
- Cholbam (cholic acid): Indicated for bile acid synthesis disorders and Zellweger spectrum disorders. Revenue generated from Cholbam for FY2023 was $42.3 million. Competitors include other bile acid therapies and supportive care treatments.
Market Dynamics
Industry Overview
The rare disease therapeutics market is a growing segment of the pharmaceutical industry. It is driven by unmet medical needs and regulatory incentives. The sector is competitive, with companies developing novel therapies and seeking orphan drug designations.
Positioning
Travere Therapeutics is positioned as a company focused on rare kidney diseases, particularly IgAN, with Filspari being its key growth driver. Its competitive advantage lies in addressing a specific unmet need with a novel mechanism of action.
Total Addressable Market (TAM)
The IgAN market is estimated to be multi-billion dollars annually. Travere Therapeutics is positioned to capture a significant share of this market with Filspari, provided it obtains full FDA approval and secures favorable reimbursement.
Upturn SWOT Analysis
Strengths
- Novel therapy for IgAN (Filspari)
- Experienced management team
- Focus on rare diseases
- Orphan drug designation benefits
Weaknesses
- Reliance on a limited product portfolio
- Commercialization risks associated with new product launches
- Potential for regulatory setbacks
- Dependence on successful clinical trials
Opportunities
- Expansion of Filspari's indications
- Development of new therapies for other rare diseases
- Strategic partnerships and acquisitions
- Geographic expansion
Threats
- Competition from other IgAN therapies
- Pricing pressures and reimbursement challenges
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Novartis (NVS)
- Calliditas Therapeutics (CALT)
Competitive Landscape
Travere Therapeutics competes with established pharmaceutical companies and other biotechs in the rare disease space. Its competitive advantage relies on the novelty and efficacy of its therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the launch and ramp-up of Filspari sales.
Future Projections: Analysts project revenue growth for the coming years, driven by increased Filspari adoption and potential label expansion. Profitability is expected to improve as revenue increases.
Recent Initiatives: Focus on the global launch of Filspari and the pursuit of full FDA approval. Development of other pipeline candidates.
Summary
Travere Therapeutics is a biopharmaceutical company focused on rare kidney diseases. The launch of Filspari for IgAN is a key growth driver, but they face competition and regulatory risks. The company is not yet profitable, but revenue is projected to grow. Success is dependent on Filspari's continued success and pipeline development, and they must be watchful of competitors and regulatory setbacks.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
CALT
Calliditas Therapeutics
CALT
Calliditas Therapeutics
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance may change. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 385 | Website https://www.travere.com |
Full time employees 385 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.